Vestal Point Capital LP Invests $33.77 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Vestal Point Capital LP bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 760,000 shares of the biopharmaceutical company's stock, valued at approximately $33,767,000. Agios Pharmaceuticals accounts for about 2.6% of Vestal Point Capital LP's holdings, making the stock its 15th largest holding. Vestal Point Capital LP owned about 1.33% of Agios Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals during the 2nd quarter valued at $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals during the second quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 363 shares in the last quarter. CWM LLC increased its position in Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth about $146,000.

Agios Pharmaceuticals Stock Performance

Shares of AGIO traded up $0.73 during mid-day trading on Friday, hitting $59.39. The company's stock had a trading volume of 237,613 shares, compared to its average volume of 694,239. The firm has a market capitalization of $3.39 billion, a PE ratio of 5.16 and a beta of 0.75. The stock's 50-day moving average is $48.42 and its two-hundred day moving average is $45.23. Agios Pharmaceuticals, Inc. has a one year low of $20.96 and a one year high of $62.58.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on AGIO shares. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 27th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a research note on Friday, November 1st. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Scotiabank boosted their price target on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a "sector outperform" rating in a research report on Friday, November 1st. Finally, Raymond James reissued an "outperform" rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $52.33.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This trade represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.93% of the company's stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.